Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report.

IF 2.4 4区医学 Q3 NEUROSCIENCES

Clinical Psychopharmacology and Neuroscience Pub Date : 2022-08-31 DOI:10.9758/cpn.2022.20.3.581

Jae Hyun Ryou, Doug Hyun Han, Reeree Lee, Sun Mi Kim

引用次数: 2

Abstract

This case report aimed to discuss the efficacy of aripiprazole for dyskinesia in patients with functional movement disorder after streptococcal infection, with its biological action of modulating dopamine hyperactivity in the basal ganglia as a dopamine partial agonist. This report has shown that the [18F] N -(3-Fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane positron emission tomography findings of the patient revealed that the dopamine hyperactivity in the basal ganglia at baseline was normalized after aripiprazole treatment due to its balancing effect as a dopamine partial agonist.

Abstract Image

查看原文本刊更多论文

阿立哌唑通过调节多巴胺能活性改善链球菌感染后运动障碍1例报告。

本病例报告旨在探讨阿立哌唑作为多巴胺部分激动剂调节基底节区多巴胺亢进的生物学作用，对链球菌感染后功能性运动障碍患者运动障碍的疗效。本报告显示，患者的[18F] N -(3-氟丙基)-2β-碳乙氧基-3β-(4-碘苯基)北tropane正电子发射断层扫描结果显示，阿立哌唑治疗后，由于其作为多巴胺部分激动剂的平衡作用，基线时基底节区多巴胺亢进现象正常化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Psychopharmacology and Neuroscience NEUROSCIENCESPHARMACOLOGY & PHARMACY-PHARMACOLOGY & PHARMACY

CiteScore

4.70

自引率

12.50%

发文量

期刊介绍： Clinical Psychopharmacology and Neuroscience (Clin Psychopharmacol Neurosci) launched in 2003, is the official journal of The Korean College of Neuropsychopharmacology (KCNP), and the associate journal for Asian College of Neuropsychopharmacology (AsCNP). This journal aims to publish evidence-based, scientifically written articles related to clinical and preclinical studies in the field of psychopharmacology and neuroscience. This journal intends to foster and encourage communications between psychiatrist, neuroscientist and all related experts in Asia as well as worldwide. It is published four times a year at the last day of February, May, August, and November.